Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Onyx/Bayer Expect 2008 Launch For Nexavar In Liver Cancer

This article was originally published in The Pink Sheet Daily

Executive Summary

Companies will submit sNDA as soon as possible following study halt because of “superior overall survival efficacy.”
Advertisement

Related Content

Bayer/Onyx Submit Nexavar sNDA For Liver Cancer
Bayer/Onyx Submit Nexavar sNDA For Liver Cancer
Progen Phase III Liver Cancer Trial To Initiate In Second Half Of 2007
Progen Phase III Liver Cancer Trial To Initiate In Second Half Of 2007
Sutent Labeling Updated To Reflect First-Line Renal Cell Carcinoma Data
Bayer/Onyx Nexavar Fails Phase III Melanoma Trial
Next For Nexavar: Bayer/Onyx Initiate Phase III Lung Cancer Trial
Bayer/Onyx’ Nexavar Approved For Kidney Cancer
Bayer/Onyx’ Nexavar Approved For Kidney Cancer

Topics

Advertisement
UsernamePublicRestriction

Register

PS065619

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel